Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota.
J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1481-e1487. doi: 10.1210/clinem/dgaa728.
The elderly population is increasing faster than other segments of the population throughout the world. Age is the leading predictor for most chronic diseases and disorders, multimorbidity, geriatric syndromes, and impaired ability to recover from accidents or illnesses. Enhancing the duration of health and independence, termed healthspan, would be more desirable than extending lifespan merely by prolonging the period of morbidity toward the end of life. The geroscience hypothesis posits that healthspan can be extended by targeting fundamental aging mechanisms, rather than attempting to address each age-related disease one at a time, only so the afflicted individual survives disabled and dies shortly afterward of another age-related disease. These fundamental aging mechanisms include, among others, chronic inflammation, fibrosis, stem cell/ progenitor dysfunction, DNA damage, epigenetic changes, metabolic shifts, destructive metabolite generation, mitochondrial dysfunction, misfolded or aggregated protein accumulation, and cellular senescence. These processes appear to be tightly interlinked, as targeting any one appears to affect many of the rest, underlying our Unitary Theory of Fundamental Aging Mechanisms. Interventions targeting many fundamental aging processes are being developed, including dietary manipulations, metformin, mTOR (mechanistic target of rapamycin) inhibitors, and senolytics, which are in early human trials. These interventions could lead to greater healthspan benefits than treating age-related diseases one at a time. To illustrate these points, we focus on cellular senescence and therapies in development to target senescent cells. Combining interventions targeting aging mechanisms with disease-specific drugs could result in more than additive benefits for currently difficult-to-treat or intractable diseases. More research attention needs to be devoted to targeting fundamental aging processes.
全球范围内,老年人口的增长速度快于其他年龄段。年龄是大多数慢性疾病和障碍、多种疾病、老年综合征以及从事故或疾病中恢复能力受损的主要预测因素。延长健康和独立的时间,即所谓的健康寿命,比仅仅通过延长生命末期的发病期来延长寿命更为可取。衰老科学假说认为,通过针对基本衰老机制,可以延长健康寿命,而不是试图一次解决与年龄相关的每一种疾病,这样受影响的个体就可以在残疾状态下幸存下来,并且不久后因另一种与年龄相关的疾病而死亡。这些基本衰老机制包括慢性炎症、纤维化、干细胞/祖细胞功能障碍、DNA 损伤、表观遗传变化、代谢转变、破坏性代谢物产生、线粒体功能障碍、错误折叠或聚集蛋白积累以及细胞衰老。这些过程似乎紧密相关,因为靶向任何一个过程似乎都会影响其他许多过程,这就是我们的基本衰老机制统一理论的基础。目前正在开发针对许多基本衰老过程的干预措施,包括饮食干预、二甲双胍、mTOR(雷帕霉素的哺乳动物靶标)抑制剂和衰老细胞清除剂,这些都处于早期人体试验阶段。这些干预措施可能会带来比一次治疗一种与年龄相关的疾病更大的健康寿命获益。为了说明这些观点,我们重点关注细胞衰老和正在开发的针对衰老细胞的疗法。将针对衰老机制的干预措施与针对特定疾病的药物相结合,可能会为目前难以治疗或难以治疗的疾病带来超过累加的益处。需要投入更多的研究关注来针对基本的衰老过程。